1. Home
  2. VSTS vs AKBA Comparison

VSTS vs AKBA Comparison

Compare VSTS & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VSTS
  • AKBA
  • Stock Information
  • Founded
  • VSTS 1936
  • AKBA 2007
  • Country
  • VSTS United States
  • AKBA United States
  • Employees
  • VSTS N/A
  • AKBA N/A
  • Industry
  • VSTS
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • VSTS
  • AKBA Health Care
  • Exchange
  • VSTS Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • VSTS 819.7M
  • AKBA 861.7M
  • IPO Year
  • VSTS N/A
  • AKBA 2014
  • Fundamental
  • Price
  • VSTS $4.22
  • AKBA $2.92
  • Analyst Decision
  • VSTS Sell
  • AKBA Strong Buy
  • Analyst Count
  • VSTS 4
  • AKBA 5
  • Target Price
  • VSTS $9.13
  • AKBA $6.90
  • AVG Volume (30 Days)
  • VSTS 1.7M
  • AKBA 3.8M
  • Earning Date
  • VSTS 08-05-2025
  • AKBA 11-06-2025
  • Dividend Yield
  • VSTS 1.66%
  • AKBA N/A
  • EPS Growth
  • VSTS N/A
  • AKBA N/A
  • EPS
  • VSTS N/A
  • AKBA N/A
  • Revenue
  • VSTS $2,707,109,000.00
  • AKBA $203,733,000.00
  • Revenue This Year
  • VSTS N/A
  • AKBA $38.23
  • Revenue Next Year
  • VSTS $0.25
  • AKBA $38.17
  • P/E Ratio
  • VSTS N/A
  • AKBA N/A
  • Revenue Growth
  • VSTS N/A
  • AKBA 16.75
  • 52 Week Low
  • VSTS $3.98
  • AKBA $1.24
  • 52 Week High
  • VSTS $17.83
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • VSTS 37.66
  • AKBA 39.09
  • Support Level
  • VSTS $3.98
  • AKBA $2.91
  • Resistance Level
  • VSTS $4.37
  • AKBA $3.15
  • Average True Range (ATR)
  • VSTS 0.21
  • AKBA 0.14
  • MACD
  • VSTS 0.02
  • AKBA 0.00
  • Stochastic Oscillator
  • VSTS 29.01
  • AKBA 6.25

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: